Entegris (NASDAQ:ENTG – Get Free Report) issued an update on its fourth quarter earnings guidance on Monday morning. The company provided earnings per share guidance of $0.75-0.82 for the period, compared to the consensus earnings per share estimate of $0.94. The company issued revenue guidance of $810-840 million, compared to the consensus revenue estimate of $878.81 million. Entegris also updated its Q4 2024 guidance to 0.750-0.820 EPS.
Entegris Stock Performance
Shares of NASDAQ:ENTG traded down $4.63 during trading on Monday, hitting $102.42. The stock had a trading volume of 651,475 shares, compared to its average volume of 1,629,776. The company has a quick ratio of 2.14, a current ratio of 3.58 and a debt-to-equity ratio of 1.18. Entegris has a 12-month low of $89.09 and a 12-month high of $147.57. The stock has a market capitalization of $15.46 billion, a price-to-earnings ratio of 87.75, a price-to-earnings-growth ratio of 1.41 and a beta of 1.25. The stock has a 50-day simple moving average of $109.36 and a two-hundred day simple moving average of $121.34.
Entegris Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 20th. Investors of record on Wednesday, October 30th will be paid a $0.10 dividend. The ex-dividend date of this dividend is Wednesday, October 30th. This represents a $0.40 annualized dividend and a dividend yield of 0.39%. Entegris’s dividend payout ratio is presently 32.79%.
Wall Street Analyst Weigh In
Get Our Latest Report on Entegris
Entegris Company Profile
Entegris, Inc develops, manufactures, and supplies microcontamination control products, specialty chemicals, and advanced materials handling solutions in North America, Taiwan, China, South Korea, Japan, Europe, and Southeast Asia. It operates in three segments: Materials Solutions (MS); Microcontamination Control (MC); and Advanced Materials Handling (AMH).
Featured Stories
- Five stocks we like better than Entegris
- Stock Market Upgrades: What Are They?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Most Volatile Stocks, What Investors Need to Know
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
- Stock Splits, Do They Really Impact Investors?
- 3 Stocks That Are Potential Takeover Targets in 2025
Receive News & Ratings for Entegris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entegris and related companies with MarketBeat.com's FREE daily email newsletter.